Recently presented at the 2024 ASCO Annual Meeting and published in parallel in The Lancet Oncology, results of the OPTIMIZE-1…
en_news
Reported today during a Proffered Paper session at the ESMO Gastrointestinal Cancers Annual Congress (ESMO GI) 2024*, first health-related quality…
On the occasion of International LGBTQIA+ Pride Day, on June 28th, VHIO shows its commitment to diversity and equality. The…
Published by ESMO’s Daily Reporter, Elena Garralda’s latest On target column explores the promise of neoadjuvant immunotherapy in the treatment…
The sixth episode of the Cancer 360º podcast entitled: “Comprehensive care in oncology” is out! A chapter where the journalist…
First results of two multi-center international Phase 1 dose-escalation and -expansion clinical trials of novel T-cell bispecific antibody cibisatamab as…
Celebrated today at the General Assembly of the Organisation of European Cancer Institutes (OECI), VHIO’s Director and Head of the…
Co-authored by Jaume Capdevila, Medical Oncologist at the Vall d’Hebron University Hospital (HUVH) and Senior Investigator of the Vall d’Hebron…
The ultrasensitive liquid biopsy technique applied in this work is based on the sequencing of the entire tumour genome from…
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with…
